Cargando…
Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-ca...
Autores principales: | Kranz, Emiko, Kuhlmann, Charles J., Chan, Joshua, Kim, Patrick Y., Chen, Irvin S. Y., Kamata, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366550/ https://www.ncbi.nlm.nih.gov/pubmed/35967430 http://dx.doi.org/10.3389/fimmu.2022.877682 |
Ejemplares similares
-
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019) -
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020) -
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022) -
Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021) -
Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)